A number of blockbuster drugs are due to see their first generic versions hitting the market in 2019, as biosimilars of major brands are also being launched. Go deeper into the biosimilars and generics that will premiere this year, a lineup that includes generic versions of blockbusters like Restasis, Lyrica, Advair, and Sensipar, and biosimilars of Avastin, Herceptin, and Rituxan. Find out from Scrip how 2019 is shaping up to be huge for both the biosimilars and generics industries.